Yuri Milner

The dimension applies because Milner is described as backing science and longevity-related efforts, but the provided evidence contains almost no articulated public vision for ending aging, reversing decline, or extending healthy lifespan. The single vision-related signal is a meta-level statement about philanthropy and reported Altos Labs backing, not a concrete, durable, or specific vision.

The provided evidence describes Yuri Milner as a technology investor and science philanthropist, not as someone with direct scientific output or measurable citation impact. With no citation metrics, authored papers, clinical trials, or independently corroborated scientific achievements, scientific_impact is inapplicable on the supplied evidence.

No evidence of direct scientific output, citation impact, authored papers, clinical trials, or independently documented scientific achievements for this hero.

The dimension applies because the evidence links Yuri Milner to longevity-related capital deployment through reported backing of Altos Labs. However, the evidence provides only one investment, no disclosed amount, no donation total, and no primary or independent corroboration. Under the independence gate, the unknown-independence dossier evidence cannot justify a high score, so the score remains modest with low confidence.

Strategic taste applies because Milner has at least one reported longevity-related backing, but the evidence is too thin to establish thesis coherence, early or contrarian timing, counterfactual importance, or a precise investment rationale. Altos Labs is a relevant and potentially important longevity biotechnology bet, yet the provided record does not show when, how much, at what stage, or why he backed it.

The dimension applies because the evidence indicates Yuri Milner founded or helped seed Altos Labs, a longevity-related company, which is a field-building organizational contribution. However, the evidence is very thin, includes no active donation-created programs, and lacks primary or independent corroboration of the specific field-creation impact.

The dimension applies because Yuri Milner is described as an investor and science philanthropist with longevity-related backing, but the provided evidence contains no concrete bravery exhibits: no public contrarian stance, no career or reputational sacrifice, no quantified bet relative to capacity, no sustained conviction under criticism, and no self-experimentation or personal risk signal. A minimal score is warranted only for reported backing of longevity-related efforts, which may indicate some conviction but is not enough to establish public risk-taking.

The dimension applies because Milner is described as an investor and science philanthropist with reported backing of Altos Labs, which could plausibly create second-order leverage. However, the provided evidence only establishes one longevity-related backed organization and gives no corroborated details on attracting talent, capital, collaborators, public legitimacy, policy attention, founders, or follow-on projects. The lone source has unknown independence, so it cannot support a high result score.